Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1B2 | O75343 | 8/20 | 0.40 |
| ▸ | GUCY1A2 | P33402 | 8/20 | 0.40 |
| ▸ | GUCY1A1 | Q02108 | 8/20 | 0.40 |
| ▸ | GUCY1B1 | Q02153 | 8/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RARA | P10276 | 1/20 | 0.34 |
| ▸ | RARB | P10826 | 1/20 | 0.34 |
| ▸ | RARG | P13631 | 1/20 | 0.34 |
| ▸ | GCK | P35557 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPD | P32754 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26670547 | 0.92 | GUCY1B2 (0.42) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1SMN1; SMN2 | |
| SCHEMBL26670552 | 0.91 | GUCY1B2 (0.40) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1SMN1; SMN2 | |
| SCHEMBL26670493 | 0.91 | GUCY1B2 (0.40) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1SMN1; SMN2 | |
| SCHEMBL30668934 | 0.89 | GUCY1B2 (0.39) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1SMN1; SMN2 | |
| SCHEMBL26829336 | 0.89 | GUCY1B2 (0.39) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1SMN1; SMN2 | |
| SCHEMBL26829246 | 0.89 | GUCY1B2 (0.42) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1SMN1; SMN2 | |
| SCHEMBL30668953 | 0.89 | GUCY1B2 (0.42) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1SMN1; SMN2 | |
| SCHEMBL30668948 | 0.84 | PARP10 (0.41) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1SMN1; SMN2 | |
| SCHEMBL26829249 | 0.84 | PARP10 (0.41) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1SMN1; SMN2 | |
| SCHEMBL26670509 | 0.84 | GUCY1B2 (0.39) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376468-A1 | PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-12-11 | — | — | US | disclosed |
| EP-4499636-A2 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023230542-A2 | PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023230542-A2 | PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250376468-A1 | PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | TRPV3, TRPM5, TRPM4 | GUCY1B2 3171/4885GUCY1A2 3012/4885GUCY1A1 2710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.